MedTrace Logo

Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study

NCT02636101 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 603

Last updated 2019-12-13

No results posted yet for this study

Summary

This study aims to describe the patient population treated and the real-life patients' experiences with Xamiol®gel in the long term, up to 52 weeks management of body psoriasis vulgaris in Russia. The result will increase the knowledge on Xamiol®gel enabling dermatologists and patients to optimize its use in the long term management of psoriasis.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

Calcipotriol/betamethasone dipropionate gel

Topical treatment of psoriasis plaques located on the body

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Dmitry Petrunin, MD, PhD · LEO Pharmaceutical Products LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-02-15
Completion
2018-02-15

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02636101 on ClinicalTrials.gov